Distinct Effects of Soluble and Membrane‐Bound Fas Ligand on Fibroblast‐like Synoviocytes From Rheumatoid Arthritis Patients

Abstract

Our findings suggest that sFasL is a disease promoter in RA, a finding consistent with previous reports describing a tumor-promoting role of FasL. Therefore, blocking of sFasL could be a therapeutic strategy for RA.